Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Travoprost

FDA-approved product (solution/drops, ophthalmic), marketed as Idose Tr, Izba, Travatan and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Travoprost
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Glaucoma
  • Ocular hypertension
  • Open-angle glaucoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Prostaglandin analogues
FDA pharmacologic class
Prostaglandin Analog FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Travoprost in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Travoprost with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effects of Travoprost on Neovascular Glaucoma

    NCT00441181 · start 2008-01

    Registered record
    Registry ID
    NCT00441181
    Conditions
    Neovascular Glaucoma
    Interventions
    Travoprost
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2008-01
    Completion
    2008-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeovascular Glaucoma
    InterventionTravoprost
    PhaseNot applicable
    Registry statusWithdrawn

  • Adherence Assessment With Travalert Dosing Aid

    NCT00508469 · start 2007-10

    Registered record
    Registry ID
    NCT00508469
    Conditions
    Open-angle Glaucoma; Ocular Hypertension
    Interventions
    Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav); Travoprost 0.004% eye drops; Timolol 0.05% eye drops; Travalert Dosing Aid
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-10
    Completion
    2010-01
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-angle Glaucoma; Ocular Hypertension
    InterventionTravoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav); Travoprost 0.004% eye drops; Timolol 0.05% eye drops; Travalert Dosing Aid
    PhasePhase 4
    Registry statusCompleted

  • Value of an Intervention to Enhance Adherence in Glaucoma Patients

    NCT00756184 · start 2007-09

    Registered record
    Registry ID
    NCT00756184
    Conditions
    Glaucoma
    Interventions
    TDA adherence monitor for travoprost therapy; TDA and travoprost monotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-09
    Completion
    2009-09
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionTDA adherence monitor for travoprost therapy; TDA and travoprost monotherapy
    PhasePhase 4
    Registry statusCompleted

  • Argon Laser Peripheral Iridoplasty for Primary Angle Closure Glaucoma

    NCT00980473 · start 2007-09

    Registered record
    Registry ID
    NCT00980473
    Conditions
    Glaucoma
    Interventions
    Argon Laser Iridoplasty; Travatan/ Timolol/Azopt
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2007-09
    Completion
    Not recorded
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionArgon Laser Iridoplasty; Travatan/ Timolol/Azopt
    PhasePhase 3
    Registry statusUnknown

  • IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension

    NCT00527501 · start 2007-08

    Registered record
    Registry ID
    NCT00527501
    Conditions
    Open-angle Glaucoma; Ocular Hypertension
    Interventions
    Travoprost/brinzolamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-08
    Completion
    2007-12
    Enrolment
    136

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-angle Glaucoma; Ocular Hypertension
    InterventionTravoprost/brinzolamide
    PhasePhase 2
    Registry statusCompleted

  • Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers

    NCT00468988 · start 2007-05

    Registered record
    Registry ID
    NCT00468988
    Conditions
    Glaucoma
    Interventions
    Travatan® Z; Xalatan®
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-05
    Completion
    2007-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionTravatan® Z; Xalatan®
    PhasePhase 4
    Registry statusCompleted

  • A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

    NCT00465803 · start 2007-03

    Registered record
    Registry ID
    NCT00465803
    Conditions
    Open-angle Glaucoma; Ocular Hypertension
    Interventions
    Travoprost 0.004%/timolol 0.5% ophthalmic solution; Travoprost ophthalmic solution, 0.004%; Timolol maleate ophthalmic solution, 0.5%
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-03
    Completion
    Not recorded
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-angle Glaucoma; Ocular Hypertension
    InterventionTravoprost 0.004%/timolol 0.5% ophthalmic solution; Travoprost ophthalmic solution, 0.004%; Timolol maleate ophthalmic solution, 0.5%
    PhasePhase 3
    Registry statusCompleted

  • Results of Mass Switch From Latanoprost to Travoprost

    NCT00347126 · start 2006-04

    Registered record
    Registry ID
    NCT00347126
    Conditions
    Glaucoma
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-04
    Completion
    2008-04
    Enrolment
    372

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • 24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination

    NCT00331240 · start 2006-03

    Registered record
    Registry ID
    NCT00331240
    Conditions
    Primary Open Angle Glaucoma; Exfoliation Syndrome
    Interventions
    travoprost/timolol fixed combination; placebo (artificial tears)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-03
    Completion
    2007-02
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open Angle Glaucoma; Exfoliation Syndrome
    Interventiontravoprost/timolol fixed combination; placebo (artificial tears)
    PhasePhase 3
    Registry statusCompleted

  • Phase III Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients

    NCT00288951 · start 2004-10

    Registered record
    Registry ID
    NCT00288951
    Conditions
    Open-angle Glaucoma; Ocular Hypertension
    Interventions
    Travoprost 0.004% with and without BAK
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-10
    Completion
    2005-06
    Enrolment
    690

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-angle Glaucoma; Ocular Hypertension
    InterventionTravoprost 0.004% with and without BAK
    PhasePhase 3
    Registry statusCompleted

  • A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

    NCT00293800 · start 2004-07

    Registered record
    Registry ID
    NCT00293800
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution; Latanoprost 0.005% Ophthalmic Solution (XALATAN); Timolol 0.5% Ophthalmic Solution; Timolol Vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-07
    Completion
    2005-12
    Enrolment
    173

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    InterventionTravoprost 0.004%/Timolol 0.5% Ophthalmic Solution; Latanoprost 0.005% Ophthalmic Solution (XALATAN); Timolol 0.5% Ophthalmic Solution; Timolol Vehicle
    PhasePhase 3
    Registry statusCompleted

  • A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

    NCT00293787 · start 2004-06

    Registered record
    Registry ID
    NCT00293787
    Conditions
    Open-angle Glaucoma; Ocular Hypertension
    Interventions
    Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution; Timolol Vehicle; Latanoprost 0.005% Ophthalmic Solution (XALATAN); Timolol Maleate Ophthalmic Solution 0.5%
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-06
    Completion
    2005-08
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-angle Glaucoma; Ocular Hypertension
    InterventionTravoprost 0.004% / Timolol 0.5% Ophthalmic Solution; Timolol Vehicle; Latanoprost 0.005% Ophthalmic Solution (XALATAN); Timolol Maleate Ophthalmic Solution 0.5%
    PhasePhase 3
    Registry statusCompleted

  • Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan

    NCT00121147 · start 2003-09

    Registered record
    Registry ID
    NCT00121147
    Conditions
    Open Angle Glaucoma; Ocular Hypertension; Pseudoexfoliation Syndrome
    Interventions
    Travatan; Azopt; Alphagan P
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-09
    Completion
    2005-10
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma; Ocular Hypertension; Pseudoexfoliation Syndrome
    InterventionTravatan; Azopt; Alphagan P
    PhaseNot applicable
    Registry statusCompleted

  • A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension

    NCT00311389 · start 2003-01

    Registered record
    Registry ID
    NCT00311389
    Conditions
    Glaucoma, Open-angle; Ocular Hypertension
    Interventions
    Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution; Latanoprost 0.005%/Timolol 0.005% ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-01
    Completion
    2004-09
    Enrolment
    408

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open-angle; Ocular Hypertension
    InterventionTravoprost 0.004%/Timolol maleate 0.5% ophthalmic solution; Latanoprost 0.005%/Timolol 0.005% ophthalmic solution
    PhasePhase 3
    Registry statusCompleted

  • Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US

    NCT00847483 · start 2002-01

    Registered record
    Registry ID
    NCT00847483
    Conditions
    Glaucoma; Ocular Hypertension
    Interventions
    latanoprost 0.005% ophthalmic solution; Travoprost 004% sterile ophthalmic solution; Bimatoprost .03% sterile ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-01
    Completion
    2002-08
    Enrolment
    375

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Ocular Hypertension
    Interventionlatanoprost 0.005% ophthalmic solution; Travoprost 004% sterile ophthalmic solution; Bimatoprost .03% sterile ophthalmic solution
    PhasePhase 4
    Registry statusCompleted